Biocept Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Antonino Morales

Chief executive officer

US$781.6k

Total compensation

CEO salary percentage46.8%
CEO tenureless than a year
CEO ownershipn/a
Management average tenure3.9yrs
Board average tenure6.1yrs

Recent management updates

Recent updates

Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For Growth

Apr 17
Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For Growth

Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position

Nov 23
Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position

Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) Earnings

Aug 19
Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) Earnings

Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time Being

Jul 03
Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time Being

Biocept and CLEARED4 ink collaboration agreement

Jun 09

Biocept enters COVID-19 testing partnership

Apr 28

Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price Gain

Mar 13
Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price Gain

We're Keeping An Eye On Biocept's (NASDAQ:BIOC) Cash Burn Rate

Jan 26
We're Keeping An Eye On Biocept's (NASDAQ:BIOC) Cash Burn Rate

Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?

Dec 22
Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?

Biocept's assays viable and sensitive for detecting tumor cells and biomarkers

Nov 20

Biocept +4% on COVID-19 testing update

Nov 12

CEO Compensation Analysis

How has Antonino Morales's remuneration changed compared to Biocept's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023n/an/a

-US$31m

Mar 31 2023n/an/a

-US$37m

Dec 31 2022US$782kUS$366k

-US$32m

Sep 30 2022n/an/a

-US$25m

Jun 30 2022n/an/a

-US$16m

Mar 31 2022n/an/a

-US$8m

Dec 31 2021US$57kn/a

-US$3m

Compensation vs Market: Antonino's total compensation ($USD781.63K) is about average for companies of similar size in the US market ($USD738.70K).

Compensation vs Earnings: Antonino's compensation has increased whilst the company is unprofitable.


CEO

Antonino Morales (67 yo)

less than a year

Tenure

US$781,631

Compensation

Mr. Antonino Morales serves as Director of Biocept, Inc., since July 20, 2021 and served as its Interim Chief Financial Officer since February 15, 2022 until June 21, 2023 and serves as its Chief Executive...


Leadership Team

NamePositionTenureCompensationOwnership
Antonino Morales
CEO, President & Directorless than a yearUS$781.63kno data
Darrell Taylor
Chief Legal Officer1.7yrsUS$773.28k0%
$ 0
Soon Hahn
Founder26.8yrsno datano data
Rob Walsh
VP & Controllerless than a yearno datano data
Philippe Marchand
Chief Operating Officer1.6yrsno datano data
Pavel Tsinberg
Director of Technology Development6.1yrsno datano data
David Moskowitz
Vice President of Strategy & Corporate Communications7yrsno datano data
Veena Singh
Senior Medical Director8.8yrsUS$577.58kno data

3.9yrs

Average Tenure

59yo

Average Age

Experienced Management: BIOC's management team is considered experienced (3.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Antonino Morales
CEO, President & Director2.3yrsUS$781.63kno data
Ivor Royston
Independent Director13.8yrsUS$65.21k0.000080%
$ 2.1
Linda Rubinstein
Independent Director2.3yrsUS$57.26k0%
$ 0
Quyen Dao-Haddock
Independent Directorless than a yearUS$13.32k0%
$ 0
Marsha Chandler
Independent Vice Chairman of the Board9.9yrsUS$70.21k0.000040%
$ 1.1
Fred Hirsch
Member of Clinical Advisory Boardno datano datano data
Bruce Gerhardt
Independent Chairman of the Board13yrsUS$67.71k0.00057%
$ 15.3

6.1yrs

Average Tenure

72yo

Average Age

Experienced Board: BIOC's board of directors are considered experienced (6.1 years average tenure).